Cellectar Biosciences
Pipeline (11 active programs)
iopofosine I 131
iopofosine · CLR 131CLR 125
CLR 121125CLR 225
CLR 121225iopofosine
CLR 121125
- Undisclosed indication
Technology platforms
PDC
Phospholipid drug conjugate (PDC) / phospholipid ether drug conjugate delivery platform that specifically targets cancer cells; enables radioconjugate programs (phospholipid radioconjugates, PRCs) designed to deliver radioisotopes directly to cancer cells while limiting exposure to healthy cells; focus area: oncology
Phospholipid Drug Conjugate
PDC (Phospholipid Drug Conjugate) delivery platform for cancer cell-targeting treatments; enables targeted delivery of radioisotopes and chemotherapeutics to cancer cells with improved efficacy and reduced off-target effects across multiple oncology indications
Biotech Distilled coverage (1)
Articles open on Substack. Some deep dives are subscriber-only.